Dexmedetomidine for Refractory Pain in Palliative Cancer Patients
NCT07885475
Summary
The goal of this study is to find out whether the medication dexmedetomidine can be a safe and effective additional treatment for cancer patients whose pain is not well controlled by standard pain medicines (such as opioids). The study includes 30 palliative care patients who still have significant pain despite standard pain treatment. All participants will receive dexmedetomidine, and outcomes related to efficacy and safety will be systematically observed.
Eligibility
Inclusion Criteria: * Adult cancer patients (\>18 years), not receiving curative treatment * Treated with parenteral opioids for cancer-related pain * Indication to start dexmedetomidine treatment due to uncontrolled background pain (NRS \> 4 in a numeric rating scale (NRS 0-10)) despite hospitalization and standard pain management. Exclusion Criteria: * Dexmedetomidine hypersensitivity * Hypotension (systolic blood pressure (BP) \< 90) * Bradycardia (heart rate (HR) \< 50) * Serious heart disease or AV block grade 2 or 3 if no pacemaker. * Severe liver failure (e.g. Child-Pugh-C or similar) * Acute cerebrovascular disease * Neuraxial pain management * Patients unable to comply with trial procedures
Conditions5
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07885475